David Gaffin and Cameron Ferrey, Technology Insights
This is the third in a series of posts covering the latest clinical technology news from the 2014 Symposium on Clinical Interventional Oncology (CIO). Our coverage again centers on novel oncologic applications for imaging modalities, a theme from our previous post on using intravascular ultrasound to better assess vascular invasion in cancer patients.
New evidence suggests that positron emission tomography/computed tomography (PET/CT) is superior to conventional single-photon emission computed tomography (SPECT) for post-radioembolization imaging. If confirmed, this finding could contribute to the displacement of SPECT in the interventional oncology sector.
High-dose yttrium-90 (Y-90) microsphere radioembolization has been documented as a viable alternative to conventional bland embolization in patients with initially non-resectable hepatocellular carcinoma (HCC) due to concerns over future liver remnant (FLR) volume. As adoption of Y-90 radioembolization has grown, efforts to improve the safety and efficacy of the procedure have followed suit.
Some efforts to improve safety and efficacy have focused on the post-procedural imaging phase of the radioembolization treatment process. As a result, Y-90 PET/CT imaging has recently gained favor over conventional SPECT as a superior post-procedural technique for assessing Y-90 microsphere distribution and the extent of non-target embolization. This change is due to two key advantages of PET/CT over SPECT, which are detailed in a new study presented at CIO 2014 last month.
Improved imaging technique enables patient-specific radioembolisation dosimetry
First, PET/CT imaging provides more accurate spatial resolution than SPECT scans. Second, Y-90 PET/CT imaging enables the creation of 3-dimensional absorbed-dose maps following radioembolization.
These maps help evaluate the technical success of the procedure, but also allow for novel methods of dose modification, representing a large step forward in the development of patient-specific radioembolization dosimetry models. More accurate, patient-tailored dosimetry could improve the effectiveness of radioembolization procedures, reducing the need for follow-up treatments and mitigating associated costs.
If conclusive, these findings on the application of PET/CT for patient-specific radioembolization dosimetry calibration could also serve as another driver of oncologic PET/CT utilization, which The Advisory Board Company estimates will increase 88% in the hospital outpatient setting between 2012 and 2022.
More from Clinical Investment Insights
Subscribe to The Pipeline for more updates from this and other conferences, and contact your Dedicated Advisor to see how we can help your organisation with custom research.